Blueprint Medicines Corporation
BPMC · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $149,413 | $146,366 | $128,184 | $138,157 |
| % Growth | 2.1% | 14.2% | -7.2% | – |
| Cost of Goods Sold | $2,802 | $7,447 | $1,932 | $11,210 |
| Gross Profit | $146,611 | $138,919 | $126,252 | $126,947 |
| % Margin | 98.1% | 94.9% | 98.5% | 91.9% |
| R&D Expenses | $91,890 | $83,672 | $85,300 | $80,653 |
| G&A Expenses | $0 | $66,225 | $63,185 | $66,631 |
| SG&A Expenses | $95,807 | $96,450 | $89,926 | $89,339 |
| Sales & Mktg Exp. | $0 | $30,225 | $26,741 | $22,708 |
| Other Operating Expenses | $0 | $0 | $0 | -$1 |
| Operating Expenses | $187,697 | $180,122 | $175,226 | $169,992 |
| Operating Income | -$41,086 | -$41,203 | -$48,974 | -$43,045 |
| % Margin | -27.5% | -28.2% | -38.2% | -31.2% |
| Other Income/Exp. Net | $42,371 | -$8,081 | -$7,029 | -$6,847 |
| Pre-Tax Income | $1,285 | -$49,284 | -$56,003 | -$49,892 |
| Tax Expense | $789 | $672 | $273 | $102 |
| Net Income | $496 | -$49,956 | -$56,276 | -$49,994 |
| % Margin | 0.3% | -34.1% | -43.9% | -36.2% |
| EPS | 0.01 | -0.79 | -0.89 | -0.8 |
| % Growth | 101.3% | 11.2% | -11.2% | – |
| EPS Diluted | 0.01 | -0.79 | -0.89 | -0.8 |
| Weighted Avg Shares Out | 63,600 | 63,600 | 63,381 | 62,854 |
| Weighted Avg Shares Out Dil | 63,600 | 63,600 | 63,381 | 62,854 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $10,393 | $11,150 | $9,936 |
| Interest Expense | $8,129 | $18,168 | $18,766 | $16,800 |
| Depreciation & Amortization | -$34,242 | $4,001 | $3,863 | $3,617 |
| EBITDA | -$41,086 | -$27,115 | -$33,374 | -$29,475 |
| % Margin | -27.5% | -18.5% | -26% | -21.3% |